AZILSARTAN MEDOXOMIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AZILSARTAN MEDOXOMIL (AZILSARTAN MEDOXOMIL).
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
| Metabolism | Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes esterase-mediated hydrolysis to azilsartan. |
| Excretion | Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged) |
| Half-life | Terminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours. |
| Protein binding | High (>99%) to serum albumin. |
| Volume of Distribution | Vd of about 16 L (0.23 L/kg for a 70 kg individual); indicates limited extravascular distribution. |
| Bioavailability | Oral bioavailability approximately 60% under fed conditions (food reduces absorption); absolute bioavailability not determined in humans. |
| Onset of Action | Oral: 1-2 hours for peak plasma concentration; antihypertensive effect begins within 2-3 hours. |
| Duration of Action | Duration of antihypertensive effect exceeds 24 hours; steady state achieved by day 7. |
40 mg orally once daily. May increase to 80 mg once daily if needed.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥15 mL/min/1.73 m². Not recommended for GFR <15 mL/min/1.73 m² due to lack of data. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment recommended; initiate at 40 mg once daily. Monitor renal function and blood pressure carefully due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AZILSARTAN MEDOXOMIL (AZILSARTAN MEDOXOMIL).
| Breastfeeding | No data on presence in human milk. Manufacturer recommends discontinuing breastfeeding or drug due to potential risk. M/P ratio unknown. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal anuria, hypotension, and death. |
| Fetal Monitoring |
■ FDA Black Box Warning
none
| Serious Effects |
["Pregnancy (second and third trimesters)","Concomitant use with aliskiren in patients with diabetes or renal impairment (eGFR <60 mL/min)"]
| Precautions | ["Fetal toxicity: avoid use in pregnancy","Hypotension in volume-depleted patients","Renal impairment: monitor renal function","Hyperkalemia: monitor potassium levels"] |
| Food/Dietary | No significant food interactions; can be taken with or without food. Avoid excessive potassium intake from high-potassium foods (e.g., bananas, oranges, spinach, potatoes) or potassium-containing salt substitutes. Limit alcohol intake as it may increase blood pressure or cause dizziness. |
Loading safety data…
| Monitor fetal growth via ultrasound, assess amniotic fluid volume (oligohydramnios), and fetal renal function. Postnatal monitoring of infant for hypotension and hyperkalemia. |
| Fertility Effects | No human data; animal studies at high doses showed reduced fertility. Effects likely mediated by altered renin-angiotensin system. |
| Clinical Pearls |
| Azilsartan medoxomil has the highest affinity for AT1 receptors among ARBs; may cause a rapid decrease in blood pressure in volume-depleted patients; avoid use in pregnancy (Category D); monitor renal function and serum potassium; less CYP450 interaction potential than losartan or irbesartan; can be taken without regard to meals; dose adjustment not required in mild-to-moderate hepatic impairment. |
| Patient Advice | Take once daily at the same time each day with or without food. · Avoid becoming dehydrated; drink adequate fluids unless directed otherwise. · Do not use if pregnant or planning to become pregnant; notify your doctor immediately if pregnancy occurs. · Do not take with aliskiren if you have diabetes or renal impairment. · Report any signs of angioedema (swelling of face, lips, tongue, difficulty breathing) or severe dizziness. · May cause dizziness, especially during first few days; avoid driving until you know how the medication affects you. · Avoid potassium supplements and salt substitutes containing potassium unless approved by your doctor. · Do not stop taking the medication without talking to your doctor. |